Testing a new multi-stage malaria vaccine in adults and children
Part of Infections clinical trials.
This trial tests a new combination of experimental malaria vaccines to see if they are safe and help protect against malaria. It includes both adults and young children in malaria-affected areas.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be either a healthy adult 18-35 years old, or a healthy child 5-17 months old.
- Women must not be pregnant and must use effective birth control for 3 months after the last vaccine dose.
- You must live in a study area village and be available for all visits and follow-up.
- You cannot have serious health conditions like sickle cell disease, cancer, or a weak immune system.
- You cannot have received any malaria vaccine before, or any other vaccine in the last 14 days.
- You cannot be taking certain medications, have HIV, hepatitis B or C, or be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests a new vaccine meant to protect young children against malaria. If you qualify, your baby would get the study vaccine and be followed for about 12 months to check safety and early signs of protection.
This study looks at how well the R21/Matrix-M malaria vaccine works and how safe it is in children who received it. It compares children who got malaria (or died) to healthy children who also got the vaccine.
This study tests a new malaria vaccine in healthy adults. You will receive the vaccine and then be exposed to the malaria parasite in a controlled setting to check if the vaccine protects you.
This trial tests a new malaria drug (MMV055), alone or with another drug (MMV371), to see if it is safe and how the body processes it. It is for healthy people who want to help find new malaria treatments.
This study tests a new long-acting injection to prevent malaria. It checks safety and how the body handles the drug in healthy adults and adolescents in Rwanda.
This study tests a genetically modified malaria parasite that is intentionally given to healthy volunteers through a mosquito bite. The goal is to see if it is safe and to learn how the immune system responds, which could help develop a malaria vaccine.
Hear when a new Malaria Falciparum trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.